ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Taisho Pharmaceutical Holdings Co., Ltd.

  • 9,530.00 JPY
  • +20.00
  • +0.21%
  • Japan
    May 20, 2019
  • Ticker
    TKS(4581)
  • Prev. close
    9,510
  • Market cap (JPY)
    857,228.12M
  • Market cap (USD)
    7,788.02M
  • Shares
    90.13M

Business Summary

Taisho Pharmaceutical Holdings Co. Ltd. engages in the management and administration of its group companies that manufactures and sells over-the-counter (OTC) drugs, foods, and other goods, etc. It operates through the following segments: Self-Medication and Prescription Pharmaceutical. The Self-Medication segment conducts research and development (R&D), manufacturing and sale of over-the-counter drugs, quasi-drugs, food, and general medical and hygiene supplies. The Prescription Pharmaceutical segment handles R&D, manufacturing, and sale of ethical drugs. It also provides the manufacture and sale of prescription pharmaceuticals; and businesses incidental or related thereto. The company was founded on October 3, 2011 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue261,369M2,356.91M
Gross Profit170,163M1,534.45M
Operating income31,212M281.45M
Income before tax64,484M581.48M
Net income48,594M438.19M
EBITDA42,502M383.26M
Diluted EPS608.225.48
Dividends Per Share1100.99
Total Assets821,782M7,424.51M
Total liabilities97,643M882.17M
Total equity712,972M6,441.45M
Operating cash flow19,222M173.33M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 290,489M 289,956M 279,750M 280,138M 261,369M
Gross Profit 178,249M 176,813M 178,225M 182,984M 170,163M
Operating income 31,974M 28,878M 31,965M 36,977M 31,212M
Income before tax 40,162M 35,809M 41,956M 48,070M 64,484M
Net income 24,528M 22,473M 28,781M 31,679M 48,594M
EBITDA 44,914M 41,351M 43,635M 48,357M 42,502M
Diluted EPS 302.41 277.60 359.93 396.20 608.22
Dividends Per Share 110 100 110 110 110
Total Assets 768,092M 759,049M 771,222M 800,157M 821,782M
Total liabilities 114,850M 115,922M 106,132M 108,838M 97,643M
Total equity 640,056M 629,249M 649,938M 675,231M 712,972M
Operating cash flow 33,714M 43,058M 40,066M 39,852M 19,222M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 2,644.25M 2,414.60M 2,583.40M 2,527.58M 2,356.91M
Gross Profit 1,622.56M 1,472.40M 1,645.85M 1,650.99M 1,534.45M
Operating income 291.05M 240.48M 295.18M 333.62M 281.45M
Income before tax 365.58M 298.19M 387.45M 433.71M 581.48M
Net income 223.27M 187.14M 265.78M 285.82M 438.19M
EBITDA 408.84M 344.34M 402.95M 436.30M 383.26M
Diluted EPS 2.75 2.31 3.32 3.57 5.48
Dividends Per Share 1.00 0.83 1.01 0.99 0.99
Total Assets 6,404.76M 6,753.40M 6,921.13M 7,523.80M 7,424.51M
Total liabilities 957.68M 1,031.38M 952.45M 1,023.39M 882.17M
Total equity 5,337.13M 5,598.54M 5,832.70M 6,349.13M 6,441.45M
Operating cash flow 306.89M 358.56M 369.99M 359.56M 173.33M

Valuation Measures

Mar 2019
PER17.32
ROA5.99%
ROE7.00%
Operating margin11.94%
Profit margin18.59%

Key executives

  • President & Representative Director: Akira Uehara
  • Director, Head-Audit, Finance & Legal Affairs: Ken Uehara
  • Head-Information Technology Planning: Osamu Kitatani
  • Director & Executive Vice President: Shigeru Uehara
  • Director, Head-Personnel & General Affairs: Tetsu Watanabe

Shareholders

  • The Uehara Memorial Foundation (16.6%)
  • Taisho Pharmaceutical Holdings Co., Ltd. (11.3%)
  • UEHARA SHOJI (8.7%)
  • Sumitomo Mitsui Financial Group, Inc. (5.1%)
  • Uehara Museum Foundation (4.3%)
  • Mitsubishi UFJ Financial Group, Inc. (4.0%)
  • UEHARA AKIRA (2.3%)
  • Kajima Corp. (1.8%)
  • Sumitomo Chemical Pension Fund (1.6%)
  • Sumitomo Chemical Co., Ltd. (1.5%)

Contact Details

Related Companies

  • Kosei SA de CV
  • DHG Pharmaceutical Joint Stock Company
  • Biofermin Pharmaceutical Co., Ltd.
  • Taisho Pharmaceutical Co., Ltd.

Competitors

  • Monster Beverage Corporation
  • LT Group, Inc.
  • Infraestructura Energetica Nova SAB de CV
Last Updated on 20 May, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends May 26th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media